Search

The purpose of the study was to assess the prevalence of post-stroke pain and the effectiveness of its diagnosis and treatment in the conditions of university clinic. It was shown that the frequency of post-stroke pain syndrome is 55.8% of the total number of patients with PPS. The pain in the shoulder joint of the paretic limb is most often recorded, due to the subluxation of the humerus, which is recorded in 28.3% of patients with PPS during hospital stay and 20.3% in the first weeks after discharge. The frequency of PPS of the central genesis is 31.1%. Syndrome of complex regional pain occurs in 4.4% of patients, pain associated with spasticity – in 13.0%. The use of visual analog scales makes it possible to diagnose post-stroke pain syndrome in patients who are conscious and have no significant cognitive deficits. With the application of complex treatment of pain syndrome, a satisfactory clinical effect is achieved in all patients, and the best response to treatment was in patients with pain in the shoulder joint of the paretic limb due to the subluxation of the head of the humerus.

Considerable evidence now exists to show that that the relative biological effectiveness (RBE) changes considerably along the proton depth-dose distribution, with progressively higher RBE values at the distal part of the modulated, or spread out Bragg peak (SOBP) and in the distal dose fall-off (DDF). However, the highly variable nature of the existing studies (with regards to cell lines, and to the physical properties and dosimetry of the various proton beams) precludes any consensus regarding the RBE weighting factor at any position in the depth-dose profile. We have thus conducted a systematic study on the variation in RBE for cell killing for two clinical modulated proton beams at Indiana University and have determined the relationship between the RBE and the dose-averaged linear energy transfer (LETd) of the protons at various positions along the depth-dose profiles. Clonogenic assays were performed on human Hep2 laryngeal cancer cells and V79 cells at various positions along the SOBPs of beams with incident energies of 87 and 200 MeV. There was a marked variation in the radiosensitivity of both cell lines along the SOBP depth-dose profile of the 87 MeV proton beam. Using Hep2 cells, the D(0.1) isoeffect dose RBE values (normalized against (60)Co) were 1.46 at the middle of SOBP, 2.1 at the distal end of the SOBP and 2.3 in the DDF. For V79 cells, the D(0.1) isoeffect RBE for the 87 MEV beam were 1.23 for the proximal end of the SOBP: 1.46 for the distal SOBP and 1.78 for the DDF. Similar D(0.1) isoeffect RBE values were found for Hep2 cells irradiated at various positions along the depth-dose profile of the 200 MeV beam. Our experimentally derived RBE values were significantly correlated (P = 0.001) with the mean LETd of the protons at the various depths, which confirmed that proton RBE is highly dependent on LETd. These in vitro data suggest that the RBE of the proton beam at certain depths is greater than 1.1, a value currently used in most treatment planning algorithms. Thus, the potential for increased cell killing and normal tissue damage in the distal regions of the proton SOBP may be greater than originally thought.

We report on a study of the longitudinal to transverse cross section ratio, R=sigmaL/sigmaT, at low values of x and Q2, as determined from inclusive inelastic electron-hydrogen and electron-deuterium scattering data from Jefferson Laboratory Hall C spanning the four-momentum transfer range 0.06

We present a state-of-the-art evaluation of the polarizability corrections--the inelastic nucleon corrections--to the hydrogen ground-state hyperfine splitting using analytic fits to the most recent data. We find a value Delta(pol)=1.3+/-0.3 ppm. This is 1-2 ppm smaller than the value of Delta(pol) deduced using hyperfine splitting data and elastic nucleon corrections obtained from modern form factor fits.